186595-57-3Relevant academic research and scientific papers
Ruthenium catalyzed β-C(sp3)-H functionalization on the 'privileged' piperazine nucleus
Murugesh,Bruneau, Christian,Achard, Mathieu,Sahoo, Apurba Ranjan,Sharma, Gangavaram V. M.,Suresh, Surisetti
supporting information, p. 10448 - 10451 (2017/09/25)
β-C(sp3)-H functionalization on the 'privileged' piperazine nucleus has been disclosed using ruthenium catalysis. The ruthenium catalyzed synthesis of a variety of piperazine fused indoles from ortho-piperazinyl (hetero)aryl aldehydes is presented. This transformation takes place via the dehydrogenation of piperazine followed by an intramolecular nucleophilic addition of the transient enamine moiety onto the carbonyl group and aromatization cascade.
ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES
-
Page/Page column 50-51, (2008/06/13)
The present invention relates to compounds of the formula (I) wherein R1, R2, R3, X, Y and the dashed line are defined in the specification, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use as psychotherapeutic agents.
NOVEL BENZYL(IDENE)-LACTAM DERIVATIVES
-
Page/Page column 31, (2008/06/13)
The present invention relates to novel benzyl(idene)-lactam derivatives, compounds of the formula (I) wherein R1 is a group of the formula G1 or G2 depicted below, wherein R1, R3, R6, R13, X, a, n and m are as defined herein, their pharmaceutically acceptable salts, and pharmaceutical compositions which include selective antagonists, inverse agonists and partial agonists of serotonin 1 (5-HT1) receptors, specifically, of one or both of the 5-HT1A and 5-HT1B receptors. The compounds of the invention are useful in treating or preventing depression, anxiety, obsessive compulsive disorder (OCD) and other disorders for which a 5-HT1 agonist or antagonist is indicated and have reduced potential for cardiac side effects, in particular QTc prolongation.
Synthesis and serotonergic activity of variously substituted (3-amido)phenylpiperazine derivatives and benzothiophene-4-piperazine derivatives: Novel antagonists for the vascular 5-HT1B receptor
Moloney, Gerard P.,Garavelas, Agatha,Martin, Graeme R.,Maxwell, Miles,Glen, Robert C.
, p. 305 - 321 (2007/10/03)
The synthesis and vascular 5-HT1B receptor activity of a novel series of substituted 3-amido phenylpiperazine and 4-(4-methyl-1-piperazinyl)-1- benzo[b]thiophene derivatives is described. Modifications to the amido linked sidechains of the 3-am
Aralkyl and aralkylidene heterocyclic lactams and imides
-
, (2008/06/13)
The present invention relates to compounds of the formula I wherein R1, R2, R3, X, Y and the dashed line are as defined in the specification, to intermediates for their preparation, to pharmaceutical compositions containin
Aralkyl and aralkylidene heterocyclic lactams and imides
-
, (2008/06/13)
The present invention relates to compounds of the formula I wherein R1, R2, R3, X, Y and the dashed line are as defined in the specification, to intermediates for their preparation, to pharmaceutical compositions containin
Synthesis of new benzothienylpiperazine derivatives and their characterisation at both 5HT(1A) and 5HT(1B) receptor sites
Lamothe,Pauwels,Leborgne,Halazy
, p. 132 - 142 (2007/10/03)
A new series of compounds containing a benzothienylpiperazine core and an arylpiperazine (of arylpiperidine) side chain has been prepared and evaluated as mixed 5HT(1A) and 5HT(1B) receptors antagonists. A SAR study allowed to identify compound 12h as a n
